Leo W. Jenkins Cancer Center
10
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
80.0%
8 terminated/withdrawn out of 10 trials
11.1%
-75.4% vs industry average
0%
0 trials in Phase 3/4
200%
2 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Role: lead
Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
Role: lead
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Role: lead
Treating NSCLC Minimal Stage IV With Curative Intent
Role: lead
Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC
Role: lead
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
Role: lead
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
Role: lead
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Role: lead
Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer
Role: lead
A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
Role: lead
All 10 trials loaded